Company: HROW
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001641172-25-019976
Chunk: 0

Company: HARROW, INC.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Items.

On
July 17, 2025, Harrow, Inc., through a wholly-owned subsidiary (together, “ Harrow”), announced that it had entered into a
development and commercialization agreement (the “ Agreement”) with Samsung Bioepis Co., Ltd. (“ Samsung”). Under
the terms of the Agreement, following completion of the transition of commercial rights from Biogen back to Samsung, Samsung will develop,
manufacture, and supply BYOOVIZ® (ranibizumab-nuna) and OPUVIZ TM

A
copy of the press release announcing the Agreement is filed as Exhibit 99

Item
9.01 Financial Statements and Exhibits.